DOVATO is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.[1]
Consult the interaction checker developed by the University of Liverpool to find out more about DDIs
The DOVATO blister pack
People living with HIV experiencing HIV-related stigma were 32% less likely to adhere to ART vs. those not reporting stigma (n=3,984).†,[8,9] Discreet packaging aims to reduce attention to the person’s medication, and together with indicators for the days of the week, could help people living with HIV keep their medication on track.
91% (n=51/56) of DOVATO blister pack users agree that the packaging helps them take their tablet discretely compared to 71% (n=61/86) of bottle users[10]
89% (n=50/56) of DOVATO blister pack users found that the packaging helped them remember if they had taken their tablet and 93% (n=52/56) said it helps them remember to renew their prescription[10]
91% (n=51/56) of DOVATO blister pack users like how it is packaged vs. 77% (n=66/86) of bottle users[10]
Visual representation of DOVATO in Blister Pack
*As defined in EACS guidelines. Includes the most common and clinically relevant interactions with 43 non-ARV medications, which are commonly co-prescribed with HIV therapy. Original data source: University of Liverpool HIV drug interaction data.[7] EACS guidelines state that no additional DDIs are expected when 3TC is added to other ARTs including DTG.[1,7]
†Association identified in a meta-analysis conducted in 3,984 people living with HIV from a total of 7 studies controlled for potential confounders.[8,9]
‡Each box of DOVATO contains 30 pills, packaged into 5 blister pack cards, which are 79 mm x 55 mm x 6.7 mm. 4 cards contain 7 pills, each labelled with the days of the week. 1 card contains 2 pills, which are not labelled. DOVATO should be taken once daily. Please keep each pill in the original DOVATO blister pack until use.[1]
3TC, lamivudine; AIDS, acquired immunodeficiency syndrome; ART, antiretroviral therapy; ARV, antiretroviral; BIC, bictegravir; DDI, drug—drug interaction; DTG, dolutegravir; EACS, European AIDS Clinical Society; FTC, emtricitabine; TAF, tenofovir alafenamide.
References:
- DOVATO (dolutegravir/lamivudine) Summary of Product Characteristics (SmPC)
- Schneider S et al. Infect Dis Ther. 2024; 13(4): 891–906.
- Silva Sombra I et al. Braz J Infect Dis 2021; 25(Suppl 1): 101045.
- Calza L et al. J Antimicrob Chemother 2020; 75(11): 3327–3333.
- Tan M et al. HIV Med 2019; 20(9): 634–637.
- Yagci Caglayik D et al. Poster presented at the European AIDS Conference (EACS). 25–27 October 2017. Milan, Italy. PE912.
- European AIDS Clinical Society (EACS) Guidelines. Version 13.0. October 2025
- Rueda S et al. BMJ Open 2016; 6(7): 1–15.
- Rueda S et al. BMJ Open 2016; 6(7): 1–15. (Suppl Appendix)
- O'Brien P et al. Poster presented at the British HIV association (BHIVA) spring conference. 23–25 April 2025. Brighton, United Kingdom. A145.
- Cahn P et al. AIDS 2022; 36(1): 39–48.
- Figueroa M et al. Clin Infect Dis 2025. https://doi.org/10.1093/cid/ciaf415. [Epub ahead of print].
PM-GB-DLL-WCNT-250009 | February 2026
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK via the GSK Reporting Tool or on 0800 221441.
